The Group's principal activity is to develop novel therapeutics primarily for radiology and neuropsychiatry. It currently sells a line of commercial products based on Protein A, which are used in the production of monoclonal antibodies. The Group manufactures and markets several products based on recombinant forms of Protein A. Its primary customers incorporate its Protein A products into their proprietary monoclonal antibody purification products that they sell directly to the biotechnology and pharmaceutical industry.
Alacra Alerts:
Receive alerts on the latest reports on Repligen Corporation
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
